

State/Territory:

IOWA

- ☒ (f). Nonprescription drugs (Some - select acne preparations, analgesics, antidiarrheals/antacids, antiemetics, antihistamines, cough & cold, GI stimulants/antiflatulents, insulin, NSAIDs, ophthalmics, respiratory inhalants, topical antibiotics, topical antifungals, topical keratolytics, topical pediculicides, vaginal antifungals, and nonprescription drugs previously covered as prescription drugs).
- ☐ (g). Covered outpatient drugs, which the manufacturer seeks to require as a condition of sale that associated tests or monitoring services be purchased exclusively from the manufacturer or its designee. (None)
- ☐ (h). Agents when used for the treatment of sexual or erectile dysfunction, unless such agents are used to treat a condition, other than sexual or erectile dysfunction, for which the agents have been approved by the Food and Drug Administration. (None)

SUPPLEMENTAL MEDICAID REBATE AGREEMENT

Pursuant to Section 1927 of the Act, the state has the following policies for supplemental rebates for Medicaid.

- A. CMS has authorized the State of Iowa to enter into "The Sovereign States Drug Consortium (SSDC)." A model rebate agreement between the state and a drug manufacturer for drugs provided to the Medicaid population, submitted to CMS on March 14, 2018, and entitled "Iowa Medicaid Supplemental Drug Rebate Agreement" has been authorized by CMS.
- B. CMS has authorized the State of Iowa to enter into value/outcomes-based contracts with manufacturers on a voluntary basis. The conditions of the value/outcomes-based contract would be agreed upon by both the state and manufacturer, meeting all federal requirements. These contracts will be executed on the model agreement entitled "Iowa Medicaid Value-Based Supplemental Rebate Agreement."